SELLAS Life Sciences Group Q4 2022 Earnings Report

SELLAS Life Sciences Group EPS Results

• Actual EPS: -$0.15
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

SELLAS Life Sciences Group Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

SELLAS Life Sciences Group Announcement Details

• Quarter: Q4 2022
• Date: 3/30/2023
• Time: N/A

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.